December 22, 2017

December 22, 2017

Joe Redner fighting stage 4 cancer to win

Fox 13 – Dec. 20
And Redner is beating the odds. Dr. Scott Antonia, of the Moffitt Cancer Center, says when Redner was diagnosed, the standard care was to give chemotherapy.

Distinguished Hematologist and Oncologist, Jason Brayer, MD, will be Honorably Mentioned in The Leading Physicians of the World

MENAFN – Dec. 22
Dr. Brayer currently serves as an Assistant Member of the Department of Malignant Hematology at the Moffitt Cancer Center & Research Institute, and he is a recognized expert in tumor immunology and plasma cell dysplasia. 

HCG and Cvergenx Partner to Launch Genomic Radiation Therapy

ET Health World – Dec. 21
The proprietary pGRTTM platform, developed at Cvergenx by Dr. Javier Torres-Roca, co-founder and Director, Clinical Research, Department of Radiation Oncology, Moffitt Cancer Center & Research Institute, is the first clinically validated approach to guide radiation dosage based upon the Radiosensitivity Index (RSI) of patients.  

Three things health execs need to know about CAR T-cell therapy

Managed Healthcare Executive – Dec. 21
Frederick Locke, MD, a medical oncologist at Moffitt Cancer Center, is excited that Gilead’s Yescarta (axicabtagene ciloleucel), developed by Kite Pharma, was approved by the FDA in October for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. 

Optimal Salvage Treatment for Radiorecurrent PCa Still Unclear

Renal and Urology News – Dec. 20
Julio Pow-Sang, MD, chair of genitourinary oncology at Moffitt Cancer Center in Tampa, Florida, commented that a major benefit of salvage RALP is that patients are cured if their tumors are localized.

Cvergenx and HCG Partner to Launch Genomic Radiation Therapy

BusinessWire – Dec. 19
The proprietary pGRT platform, developed at Cvergenx by Dr. Javier F. Torres-Roca, Co-founder and Director of Clinical Research, Department of Radiation Oncology, Moffitt Cancer Center & Research Institute, is the first clinically validated approach to guide radiation dosage based upon the Radiosensitivity Index (RSI) of patients. 

FOI Implements Tobacco-Free Property Policy

Patch – Dec. 19
"As a health care facility that prides itself on doing what's best for our patients, this just makes sense for us and it has been a long time coming," says Roy Sanders, M.D., President and Chief Medical Officer of Florida Orthopaedic Institute. "Many health care facilities in the area, including Moffitt Cancer Center, USF, Florida Hospital and BayCare, are already tobacco-free properties."

FSU research: 2017 marks new highs for university scientific, creative endeavors

Florida State University – Dec. 19
The university ranked fifth in Florida for funding from the NIH, ahead of heavyweights such as the Mayo Clinic in Jacksonville and the H. Lee Moffitt Cancer Center and Research Institute in Tampa.

Tampa Bay Wave welcomes three new members to board of directors

Tampa Bay News Wire – Dec. 19
Joe Hodges is an entrepreneur who has created, grown, and sold companies across the United States. … as a member on the Moffitt Cancer Center Corporate Partners Steering Committee, and was Knighted into the Order of Salvador. He also proudly serves as a member of the Advisory Council for the Dali Museum.

Interview with Dr. Alan List of Moffitt Cancer Center

Florida Trend – Dec. 18
Dr. Alan List, president and CEO of Moffitt Cancer Center, shares the latest from the front lines of the battle against cancer, describes new methods for treatments and explains cancer prevention through vaccination.

Targeted therapy and precision medicine explained

SCI – Dec. 18
Dr Robert Gillies, Chair of Moffitt's Department of Cancer Imaging and Metabolism, explains the approach, ‘The core belief of radiomics is that images aren't pictures, they're data.

Men With HPV Likely to be Reinfected With the Same Type After One Year

Infection Control Today – Dec. 15
The new study took a closer look at the many types of HPV and why they coexist. The research team, including Anna R. Giuliano, PhD, co-director of the Center for Infection Research in Cancer at Moffitt Cancer Center, analyzed data from the human papillomavirus in men (HIM) study, which tracked more than 4,000 unvaccinated men in Florida, Mexico and Brazil over a five-year period. Also published at


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.